Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Ss Hedegaard; A Hvas; E Groove; J Refìsgaard; Bianca Rocca; G Davi; S Kristensen

doi:10.1016/j.thromres.2008.12.034

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Ss Hedegaard, A Hvas, E Groove, J Refìsgaard, Bianca Rocca, G Davi, S Kristensen

Risultato della ricerca: Contributo in rivista › Articolo

36 Citazioni (Scopus)

Abstract

Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients.

Lingua originale	Inglese
pagine (da-a)	96-100
Numero di pagine	5
Rivista	Thrombosis Research
Volume	124
DOI	https://doi.org/10.1016/j.thromres.2008.12.034
Stato di pubblicazione	Pubblicato - 2009

Keywords

Adult
Aged
Aspirin
Blood Platelets
Coronary Artery Disease
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Patient Compliance
Platelet Aggregation
Platelet Aggregation Inhibitors
Tablets, Enteric-Coated
Thromboxanes
Time Factors

Accesso al documento

10.1016/j.thromres.2008.12.034

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{35b04a9190674e29be4fba787b4b469f,

title = "Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration",

abstract = "Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients.",

keywords = "Adult, Aged, Aspirin, Blood Platelets, Coronary Artery Disease, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Patient Compliance, Platelet Aggregation, Platelet Aggregation Inhibitors, Tablets, Enteric-Coated, Thromboxanes, Time Factors, Adult, Aged, Aspirin, Blood Platelets, Coronary Artery Disease, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Patient Compliance, Platelet Aggregation, Platelet Aggregation Inhibitors, Tablets, Enteric-Coated, Thromboxanes, Time Factors",

author = "Ss Hedegaard and A Hvas and E Groove and J Ref{\`i}sgaard and Bianca Rocca and G Davi and S Kristensen",

year = "2009",

doi = "10.1016/j.thromres.2008.12.034",

language = "English",

volume = "124",

pages = "96--100",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

AU - Hedegaard, Ss

AU - Hvas, A

AU - Groove, E

AU - Refìsgaard, J

AU - Rocca, Bianca

AU - Davi, G

AU - Kristensen, S

PY - 2009

Y1 - 2009

N2 - Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients.

AB - Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients.

KW - Adult

KW - Aged

KW - Aspirin

KW - Blood Platelets

KW - Coronary Artery Disease

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Compliance

KW - Platelet Aggregation

KW - Platelet Aggregation Inhibitors

KW - Tablets, Enteric-Coated

KW - Thromboxanes

KW - Time Factors

KW - Adult

KW - Aged

KW - Aspirin

KW - Blood Platelets

KW - Coronary Artery Disease

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Compliance

KW - Platelet Aggregation

KW - Platelet Aggregation Inhibitors

KW - Tablets, Enteric-Coated

KW - Thromboxanes

KW - Time Factors

UR - http://hdl.handle.net/10807/25336

U2 - 10.1016/j.thromres.2008.12.034

DO - 10.1016/j.thromres.2008.12.034

M3 - Article

SN - 0049-3848

VL - 124

SP - 96

EP - 100

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo